TY - JOUR
T1 - Screening for testicular cancer (Review)
AU - Ilic, Dragan
AU - Misso, Marie
PY - 2011
Y1 - 2011
N2 - Testicular cancer commonly affects men aged between 20 and 35 years. Screening for testicular cancer may reduce both morbidity and mortality, yet the effectiveness of any method is unknown. Equally, screening may also promote treatment procedures that are unwarranted or may adversely affect the health outcomes of the patient with no net benefit. Additionally, many organisations recommend against screening for testicular cancer due to the low incidence of testicular cancer and favourable outcomes in the absence of screening.
AB - Testicular cancer commonly affects men aged between 20 and 35 years. Screening for testicular cancer may reduce both morbidity and mortality, yet the effectiveness of any method is unknown. Equally, screening may also promote treatment procedures that are unwarranted or may adversely affect the health outcomes of the patient with no net benefit. Additionally, many organisations recommend against screening for testicular cancer due to the low incidence of testicular cancer and favourable outcomes in the absence of screening.
UR - http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007853.pub2/pdf/standard
U2 - 10.1002/14651858.CD007853.pub2
DO - 10.1002/14651858.CD007853.pub2
M3 - Article
SN - 1469-493X
VL - 2
SP - 1
EP - 10
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
M1 - CD007853
ER -
